FDA Clears First Interchangeable Biosimilar Versions of Simponi and Simponi Aria

The U.S. Food and Drug Administration has authorized the first interchangeable biosimilars for the medications Simponi and Simponi Aria. These newly approved versions, Immgolis and Immgolis Intri, are indicated for conditions such as rheumatoid arthritis and ulcerative colitis. Their interchangeable status means they can be substituted for the original drugs at the pharmacy level, potentially increasing access and affordability.